| Name | 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide |
|---|---|
| Synonyms |
UNII-5XGC17ZKUF
Radiprodil |
| Description | Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions[1]. |
|---|---|
| Related Catalog | |
| Target |
NMDA NR2B[1]. |
| In Vitro | Preincubation with Radiprodil (10 nM) restores long-term potentiation (LTP) in the presence of Aβ1-42, 3NTyr10-Aβ and Aβ1-40, but not AβpE3[2]. As for LTP, Radiprodil (10 nM) reverses the synaptic toxicity of 3NTyr-AβAβ1-40 and Aβ1-42 but not that AβpE3-42[2]. |
| In Vivo | Radiprodil could block NMDA currents in Mg2+ insensitive variants, with potencies similar to those obtained without Mg2+[3]. Radiprodil's potency is higher at pH 7.0 than at pH 7.6, suggesting that radiprodil may retain its ability to block glutamate-induced NMDA currents even under acidic conditions that manifest under long term seizures[3]. |
| References |
| Molecular Formula | C21H20FN3O4 |
|---|---|
| Molecular Weight | 397.40 |
| Exact Mass | 397.14400 |
| PSA | 95.67000 |
| LogP | 3.10320 |
| Storage condition | 2-8℃ |